On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer ‌ Richard J. Bownes, Arran K. Turnbull, Carlos Martinez-Perez, David A. Cameron, Andrew H. Sims, Olga Oikonomidou

Ստացեք ամբողջական տեքստը

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer ‌ Robert C Stein, Janet A Dunn, John MS Bartlett, Amy F Campbell, Andrea Marshall, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E Pinder, David A Cameron, Nigel Stallard, Jenny L Donovan, Christopher McCabe, Luke Hughes-Davies, Andreas Makris, on behalf of the OPTIMA Trial Management Group

Ստացեք ամբողջական տեքստը

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT ‌ Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn

Ստացեք ամբողջական տեքստը